Omeros ROA 2009-2019 | OMER

Current and historical return on assets (ROA) values for Omeros (OMER) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets. Omeros ROA for the three months ending March 31, 2019 was -106.08%.
Omeros ROA - Return on Assets Historical Data
Date TTM Net Income Total Assets Return on Assets
2019-03-31 $-0.12B $0.10B -127.70%
2018-12-31 $-0.13B $0.10B -138.42%
2018-09-30 $-0.12B $0.08B -124.03%
2018-06-30 $-0.09B $0.11B -80.55%
2018-03-31 $-0.07B $0.09B -69.57%
2017-12-31 $-0.05B $0.12B -58.89%
2017-09-30 $-0.06B $0.13B -72.03%
2017-06-30 $-0.06B $0.06B -97.67%
2017-03-31 $-0.06B $0.06B -101.64%
2016-12-31 $-0.07B $0.07B -122.52%
2016-09-30 $-0.07B $0.07B -133.33%
2016-06-30 $-0.07B $0.05B -172.09%
2016-03-31 $-0.08B $0.04B -168.65%
2015-12-31 $-0.08B $0.05B -135.71%
2015-09-30 $-0.08B $0.04B -165.59%
2015-06-30 $-0.08B $0.06B -176.47%
2015-03-31 $-0.08B $0.08B -200.00%
2014-12-31 $-0.07B $0.01B -222.56%
2014-09-30 $-0.06B $0.03B -158.27%
2014-06-30 $-0.05B $0.04B -161.90%
2014-03-31 $-0.05B $0.06B -174.07%
2013-12-31 $-0.04B $0.02B -228.57%
2013-09-30 $-0.05B $0.01B -230.00%
2013-06-30 $-0.05B $0.02B -178.22%
2013-03-31 $-0.04B $0.02B -181.82%
2012-12-31 $-0.04B $0.03B -171.43%
2012-09-30 $-0.04B $0.03B -180.22%
2012-06-30 $-0.04B $0.01B -150.54%
2012-03-31 $-0.03B $0.02B -100.00%
2011-12-31 $-0.03B $0.03B -76.82%
2011-09-30 $-0.03B $0.04B -61.18%
2011-06-30 $-0.03B $0.04B -62.79%
2011-03-31 $-0.03B $0.05B -68.18%
2010-12-31 $-0.03B $0.05B -66.30%
2010-09-30 $-0.03B $0.04B -58.88%
2010-06-30 $-0.03B $0.05B -59.88%
2010-03-31 $-0.02B $0.05B -75.41%
2009-12-31 $-0.02B $0.06B -121.74%
2009-09-30 $-0.02B $0.01B -857.14%
2009-06-30 $-0.02B $0.00B inf%
Sector Industry Market Cap Revenue
Medical Medical Products Manufacturing $0.804B $0.030B
Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders.
Stock Name Country Market Cap PE Ratio
Abbott Laboratories (ABT) United States $149.444B 29.01
Medtronic (MDT) Ireland $132.989B 19.00
Stryker (SYK) United States $76.293B 27.23
Boston Scientific (BSX) United States $58.421B 28.01
Baxter (BAX) United States $41.972B 26.45
Zimmer Biomet Holdings (ZBH) United States $24.047B 15.45
Smith & Nephew SNATS (SNN) United Kingdom $19.169B 0.00
ResMed (RMD) United States $17.375B 33.20
Canopy Growth (CGC) Canada $13.976B 0.00
Bio-Rad Laboratories (BIO) United States $8.970B 47.55
Aurora Cannabis (ACB) Canada $7.616B 75.10
Insulet (PODD) United States $7.025B 511.83
Hill-Rom Holdings (HRC) United States $6.932B 21.01
Perrigo (PRGO) Ireland $6.005B 10.15
Haemonetics (HAE) United States $5.941B 48.49
GW Pharmaceuticals (GWPH) United Kingdom $5.196B 0.00
ICU Medical (ICUI) United States $5.076B 30.28
Hutchison China MediTech (HCM) China $3.869B 0.00
Neogen (NEOG) United States $3.133B 50.95
NuVasive (NUVA) United States $2.997B 24.48
Agios Pharmaceuticals (AGIO) United States $2.860B 0.00
National Vision Holdings (EYE) United States $2.450B 52.20
Quidel (QDEL) United States $2.347B 24.36
Aphria (APHA) $1.783B 0.00
Cardiovascular Systems (CSII) United States $1.472B 845.60
HEXO (HEXO) $1.376B 0.00
Phibro Animal Health (PAHC) United States $1.239B 18.57
AtriCure (ATRC) United States $1.167B 0.00
VAREX IMAGING (VREX) United States $1.115B 23.67
Lantheus Holdings (LNTH) United States $1.072B 28.46
OrganiGram Holdings (OGI) Canada $0.985B 0.00
NanoString Technologies (NSTG) United States $0.910B 0.00
PetIQ (PETQ) United States $0.865B 21.00
Quanterix (QTRX) United States $0.842B 0.00
MacroGenics (MGNX) United States $0.792B 0.00
Eagle Pharmaceuticals (EGRX) United States $0.743B 20.83
Cerus (CERS) United States $0.663B 0.00
TG Therapeutics (TGTX) United States $0.610B 0.00
Surmodics (SRDX) United States $0.552B 80.18
LeMaitre Vascular (LMAT) United States $0.544B 26.35
OraSure Technologies (OSUR) United States $0.538B 24.77
Meridian Bioscience (VIVO) United States $0.486B 14.84
Zynex (ZYXI) United States $0.378B 39.10
Evolus (EOLS) United States $0.374B 0.00
Vapotherm (VAPO) United States $0.372B 0.00
Neptune Technologies & Bioresources Inc (NEPT) Canada $0.361B 0.00
Utah Medical Products (UTMD) United States $0.320B 22.16
BioLife Solutions (BLFS) United States $0.308B 96.24
Bovie Medical (APYX) United States $0.211B 0.00
Cytosorbents (CTSO) United States $0.209B 0.00
Owens & Minor (OMI) United States $0.184B 3.91
Chimerix (CMRX) United States $0.174B 0.00
Rockwell Medical (RMTI) United States $0.170B 0.00
Fonar (FONR) United States $0.142B 7.49
Female Health (VERU) United States $0.134B 0.00
BRAINSWAY LTD (BWAY) Israel $0.114B 0.00
Neurotrope (NTRP) United States $0.103B 0.00
Chembio Diagnostics (CEMI) United States $0.102B 0.00
InfuSystems Holdings (INFU) United States $0.086B 0.00
United-Guardian (UG) United States $0.084B 18.55
Surface Oncology (SURF) United States $0.084B 0.00
Oramed Pharmaceuticals (ORMP) United States $0.061B 0.00
ImmuCell (ICCC) United States $0.048B 0.00
Trinity Biotech (TRIB) Ireland $0.041B 14.17
Senestech (SNES) United States $0.037B 0.00
GUARDION HEALTH (GHSI) United States $0.031B 0.00
Conatus Pharmaceuticals (CNAT) United States $0.031B 0.00
Cellectar Biosciences (CLRB) United States $0.020B 0.00
Valeritas Holdings (VLRX) United States $0.015B 0.00
Myomo (MYO) United States $0.013B 0.00
Capricor Therapeutics (CAPR) United States $0.011B 0.00
InVivo Therapeutics Holdings (NVIV) United States $0.007B 0.00
Akers Biosciences Inc (AKER) United States $0.007B 0.00
NeuroMetrix (NURO) United States $0.005B 3.85